Company Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 487 |
| CEO | Barry E. Greene |
Contact Details
Address: 215 First Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617-299-8380 |
| Website | sagerx.com |
Stock Details
| Ticker Symbol | SAGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597553 |
| CUSIP Number | 78667J108 |
| ISIN Number | US78667J1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Barry E. Greene | President, Chief Executive Officer and Director |
| Kimi E. Iguchi CPA | Chief Financial Officer and Treasurer |
| Anne Marie Cook Esq. | Senior Vice President, General Counsel and Secretary |
| Christopher Benecchi | Chief Business Officer |
| Dr. Laura Gault M.D., Ph.D. | Chief Medical Officer |
| Matt Lasmanis | Chief Technology and Innovation Officer |
| Mike Quirk | Chief Scientific Officer |
| Ashley Kaplowitz | Director of Investor Relations |
| Erin E. Lanciani | Chief People and Experience Officer |
| Dr. Amy Schacterle Ph.D. | Senior Vice President of Research & Development Strategy and Business Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Mar 27, 2024 | SC TO-I/A | Filing |
| Mar 26, 2024 | 8-K | Current Report |
| Feb 21, 2024 | SC TO-I/A | Filing |
| Feb 14, 2024 | SC TO-I/A | Filing |
| Feb 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 14, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |